Title
Inflammation is a key risk factor for persistent seizures in neurocysticercosis
Date Issued
01 May 2018
Access level
open access
Resource Type
journal article
Publisher(s)
Wiley-Blackwell
Abstract
Objective: We conducted a retrospective, case–control study of neurocysticercosis patients to ascertain early markers that identify subjects likely to develop treatment-resistant seizures. Methods: Clinical histories and imaging studies from 38 neurocysticercosis patients who had been followed for 18 months after treatment were evaluated. Both pairwise and multifactorial analyses were conducted to identify factors associated with continued seizures. Results: Eleven of 38 patients continued to have seizures during the follow-up period. On univariate analysis, the number of neurocysticercosis lesions, number of bands on the baseline neurocysticercosis western blot, edema volumes on follow-up MRI scans, edema volume changes between baseline and follow-up images, and proportion of calcified lesions with perilesional edema were all significantly increased in subjects who had persistent seizures during the 18-month follow-up period. On multivariate analyses using recursive partition and random forest algorithms, variables associated with persistent seizures included: the number of total and calcified lesions, presence of perilesional edema, the rate of change in the lesion and edema volumes from baseline to follow-up, and the number of bands on the neurocysticercosis western blot. Interpretation: Measures of both inflammation and disease burden are key risk factors for persistent seizures despite anticonvulsant treatments in patients with neurocysticercosis. Inflammation is therefore a potentially modifiable risk factor for the frequently seen severe seizure disorders in patients with neurocysticercosis.
Start page
630
End page
639
Volume
5
Issue
5
Language
English
OCDE Knowledge area
Neurología clínica Parasitología
Scopus EID
2-s2.0-85045203590
Source
Annals of Clinical and Translational Neurology
ISSN of the container
23289503
Sponsor(s)
The original treatment study was approved by the main institutional review board at the Universidad Peruana Cayetano Heredia (IRB Code 51070, FWA 00002541) and was registered with ClinicalTrials.gov, number NCT00441285. All subjects signed informed consent prior to enrollment. The retrospective analysis was granted an exemption from the University of Illinois at Chicago IRB as all data had previously been de-identified. The original trial that provided these data was supported by NINDS grant R01 NS058405. Javier Bustos has received support from NIAID grant R01AI116456 and H. Hugo Garcia has received support from NIAID grant U19AI129909, NINDS grants U01NS086974 and R21NS094976, and FIC-NIH training grant D43TW001140. The remaining authors have no conflicts of interest or disclosures and none of the authors have any financial associations with commercial entities that were involved with the project. We acknowledge the funding support from the Chancellor’s Global Health and Well-Being Seed Grant Program of the UIC College of Medicine Center for Global Health. Dr. Herrick’s research is supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000050. This study was funded in part using support from the Chancellor’s Global Health and Well-Being Seed Grant Program of the UIC College of Medicine Center for Global Health. Dr. Herrick’s research is supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR000050. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. HG, IG, and JB are supported by FIC-NIH training grant D43 TW001140. The original trial that provided the data retrospectively assessed here was supported by NINDS grant R01 NS058405.
Sources of information: Directorio de Producción Científica Scopus